BioReference Laboratories
The firm alleges its competitors infringe its patents describing processes for finding chromosomal abnormalities in fetal cell-free DNA.
Opko Health Q3 Revenues Fall 10 Percent
Despite decreases in COVID-19 testing volume, the firm saw an increase in clinical and genomic test revenue.
BioReference Labs Acquires US Ariosa Lab NIPT Business From Roche
The business will complement BioReference's specialty health division GenPath, which offers a noninvasive prenatal screening test.
Increased Testing Revenues Boost Opko Health Q2 Revenues 47 Percent
The firm saw increases in SARS-CoV-2, clinical, and genomic testing and processed approximately 2.8 million COVID-19 PCR tests.
Opko Health Q1 Revenues More Than Double Due to COVID-19 Test Demand
The company reported revenues of $545.2 million compared to $211.5 million in the year-ago quarter, primarily driven by COVID-19 testing.
Dec 20, 2020
Oct 30, 2020
Opko Health Q3 Revenues Up 87 Percent
Jun 22, 2018
Apr 24, 2017